z-logo
open-access-imgOpen Access
Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology
Author(s) -
Stefano Comai,
Gabriella Gobbi
Publication year - 2014
Publication title -
journal of psychiatry and neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.767
H-Index - 99
eISSN - 1488-2434
pISSN - 1180-4882
DOI - 10.1503/jpn.130009
Subject(s) - melatonin , psychopharmacology , receptor , anxiolytic , melatonin receptor , neuroscience , anxiety , psychology , medicine , pharmacology , bioinformatics , psychiatry , biology
Melatonin (MLT) is a pleiotropic neurohormone controlling many physiological processes and whose dysfunction may contribute to several different diseases, such as neurodegenerative diseases, circadian and mood disorders, insomnia, type 2 diabetes and pain. Melatonin is synthesized by the pineal gland during the night and acts through 2 G-protein coupled receptors (GPCRs), MT1 (MEL1a) and MT2 (MEL1b). Although a bulk of research has examined the physiopathological effects of MLT, few studies have investigated the selective role played by MT1 and MT2 receptors. Here we have reviewed current knowledge about the implications of MT2 receptors in brain functions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom